SJURVM schreef op 14 mei 2015 19:39:
www.prnewswire.com/news-releases/brya...from initially going for $150m to $275m is a pretty good job. I have mentioned a few times that there is plenty of money for the Biotech sector.
It is nice however tosee that Galapagos is the largest IPO for a european company in that sector to come to Nasdaq.
Now people will discuss if the share price will it go up or down or sideways.
IR presentation in June
Filgotnib 24 weeks results in July
Abbvie decision by September of taking 0634 on or not
Cash in the bank to promote the pipeline of galapagos.
The road is long (2017/18 for Filgotnib?)but institutional investors have put the cash down. They can see the cash making drug when they see one.
I bought my shares at €12.50 not too long ago. Some people on this forum were in from the beginning believing in the potential. I salute you.
My last post on this forum for a little while.
I might come back when we are at €100 or so.
Enjoy.